Summit Therapeutics PLC
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.61
- Today's High:
- $1.82
- Open Price:
- $1.61
- 52W Low:
- $0.66
- 52W High:
- $5.78
- Prev. Close:
- $1.63
- Volume:
- 870515
Company Statistics
- Market Cap.:
- $1.14 billion
- Book Value:
- 0.171
- Revenue TTM:
- $220000
- Operating Margin TTM:
- -28213.18%
- Gross Profit TTM:
- $705000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -23.29%
- Return on Equity TTM:
- -699.42%
Company Profile
Summit Therapeutics PLC had its IPO on 2015-03-05 under the ticker symbol SMMT.
The company operates in the Healthcare sector and Biotechnology industry. Summit Therapeutics PLC has a staff strength of 76 employees.
Stock update
Shares of Summit Therapeutics PLC opened at $1.61 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.61 - $1.82, and closed at $1.79.
This is a +9.82% increase from the previous day's closing price.
A total volume of 870,515 shares were traded at the close of the day’s session.
In the last one week, shares of Summit Therapeutics PLC have increased by +9.82%.
Summit Therapeutics PLC's Key Ratios
Summit Therapeutics PLC has a market cap of $1.14 billion, indicating a price to book ratio of 5.9226 and a price to sales ratio of 753.9008.
In the last 12-months Summit Therapeutics PLC’s revenue was $220000 with a gross profit of $705000 and an EBITDA of $-61318000. The EBITDA ratio measures Summit Therapeutics PLC's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Summit Therapeutics PLC’s operating margin was -28213.18% while its return on assets stood at -23.29% with a return of equity of -699.42%.
In Q2.3333333333333, Summit Therapeutics PLC’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.
Summit Therapeutics PLC’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-1.16 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Summit Therapeutics PLC’s profitability.
Summit Therapeutics PLC stock is trading at a EV to sales ratio of 702.4822 and a EV to EBITDA ratio of -8.1139. Its price to sales ratio in the trailing 12-months stood at 753.9008.
Summit Therapeutics PLC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $237.37 million
- Total Liabilities
- $11.93 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $20000
- Dividend Payout Ratio
- 0%
Summit Therapeutics PLC ended 2024 with $237.37 million in total assets and $0 in total liabilities. Its intangible assets were valued at $237.37 million while shareholder equity stood at $119.60 million.
Summit Therapeutics PLC ended 2024 with $0 in deferred long-term liabilities, $11.93 million in other current liabilities, 6976000.00 in common stock, $-935423000.00 in retained earnings and $1.88 million in goodwill. Its cash balance stood at $42.12 million and cash and short-term investments were $215.01 million. The company’s total short-term debt was $2,928,000 while long-term debt stood at $0.
Summit Therapeutics PLC’s total current assets stands at $227.50 million while long-term investments were $0 and short-term investments were $172.90 million. Its net receivables were $4.61 million compared to accounts payable of $987000.00 and inventory worth $6.09 million.
In 2024, Summit Therapeutics PLC's operating cash flow was $0 while its capital expenditure stood at $20000.
Comparatively, Summit Therapeutics PLC paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.79
- 52-Week High
- $5.78
- 52-Week Low
- $0.66
- Analyst Target Price
- $5
Summit Therapeutics PLC stock is currently trading at $1.79 per share. It touched a 52-week high of $5.78 and a 52-week low of $5.78. Analysts tracking the stock have a 12-month average target price of $5.
Its 50-day moving average was $1.92 and 200-day moving average was $2.26 The short ratio stood at 9.39 indicating a short percent outstanding of 0%.
Around 2961.4% of the company’s stock are held by insiders while 326.8% are held by institutions.
Frequently Asked Questions About Summit Therapeutics PLC
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Summit Therapeutics Inc., a biopharmaceutical company, research and develops primarily oncology therapies in the United States, and the United Kingdom. The company’s product pipeline includes SMT-738, a novel class of precision antibiotics for treatment which is in preclinical stage for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. for research and develop Ivonescimab (AK112) and SMT112, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis. The company was founded in 2003 and is headquartered in Cambridge, Massachusetts.